IL97729A - Antiviral preparations containing organic metallic complexes - Google Patents

Antiviral preparations containing organic metallic complexes

Info

Publication number: IL97729A
Authority: IL; Israel
Prior art keywords: group; compound; inoculation; day; disease
Prior art date: 1990-03-30

Application number

IL9772991A

Other languages

English (en)

Hebrew (he)

Other versions

IL97729A0 (en

Inventor

David I Scheer

Original Assignee

Chai Tech Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-03-30

Filing date

1991-03-29

Publication date

1996-01-31

1991-03-29 Application filed by Chai Tech Corp filed Critical Chai Tech Corp

1992-06-21 Publication of IL97729A0 publication Critical patent/IL97729A0/xx

1996-01-31 Publication of IL97729A publication Critical patent/IL97729A/en

Links

239000000203 mixture Substances 0.000 title claims abstract description 33
230000000840 anti-viral effect Effects 0.000 title claims description 9
150000001875 compounds Chemical class 0.000 claims abstract description 35
125000000217 alkyl group Chemical group 0.000 claims abstract description 27
239000003446 ligand Substances 0.000 claims abstract description 25
239000001257 hydrogen Substances 0.000 claims abstract description 16
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 16
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 8
239000003443 antiviral agent Substances 0.000 claims abstract description 7
150000004820 halides Chemical class 0.000 claims abstract description 7
150000004703 alkoxides Chemical group 0.000 claims abstract description 6
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 4
150000002431 hydrogen Chemical class 0.000 claims abstract 6
241000700605 Viruses Species 0.000 claims description 31
241000701161 unidentified adenovirus Species 0.000 claims description 6
125000001424 substituent group Chemical group 0.000 claims description 4
241001529453 unidentified herpesvirus Species 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 6
238000000034 method Methods 0.000 abstract description 3
201000010099 disease Diseases 0.000 description 76
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 76
238000012809 post-inoculation Methods 0.000 description 56
KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 50
229940125833 compound 23 Drugs 0.000 description 50
241001465754 Metazoa Species 0.000 description 47
238000002560 therapeutic procedure Methods 0.000 description 41
241000700588 Human alphaherpesvirus 1 Species 0.000 description 29
238000011282 treatment Methods 0.000 description 22
239000000902 placebo Substances 0.000 description 18
229940068196 placebo Drugs 0.000 description 18
238000011081 inoculation Methods 0.000 description 16
241000701085 Human alphaherpesvirus 3 Species 0.000 description 13
241000701024 Human betaherpesvirus 5 Species 0.000 description 13
239000013553 cell monolayer Substances 0.000 description 13
241000701074 Human alphaherpesvirus 2 Species 0.000 description 12
238000011161 development Methods 0.000 description 10
208000022873 Ocular disease Diseases 0.000 description 9
208000015181 infectious disease Diseases 0.000 description 9
206010023332 keratitis Diseases 0.000 description 9
238000011084 recovery Methods 0.000 description 9
239000003814 drug Substances 0.000 description 8
125000004435 hydrogen atom Chemical class [H]* 0.000 description 7
230000009385 viral infection Effects 0.000 description 7
RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 6
JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
241000283973 Oryctolagus cuniculus Species 0.000 description 6
208000036142 Viral infection Diseases 0.000 description 6
210000003683 corneal stroma Anatomy 0.000 description 6
230000003247 decreasing effect Effects 0.000 description 6
238000010586 diagram Methods 0.000 description 6
229940079593 drug Drugs 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 5
229910052751 metal Inorganic materials 0.000 description 5
239000002184 metal Substances 0.000 description 5
230000009467 reduction Effects 0.000 description 5
206010066901 Treatment failure Diseases 0.000 description 4
125000004429 atom Chemical group 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical group [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 description 4
-1 halide ions Chemical class 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
238000004776 molecular orbital Methods 0.000 description 4
239000000243 solution Substances 0.000 description 4
210000003501 vero cell Anatomy 0.000 description 4
206010051559 Corneal defect Diseases 0.000 description 3
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
229910017052 cobalt Inorganic materials 0.000 description 3
229910001882 dioxygen Inorganic materials 0.000 description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
230000004044 response Effects 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
206010061818 Disease progression Diseases 0.000 description 2
206010037508 Punctate keratitis Diseases 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000010941 cobalt Substances 0.000 description 2
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
230000005750 disease progression Effects 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
239000002674 ointment Substances 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
238000011176 pooling Methods 0.000 description 2
238000009258 post-therapy Methods 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000027756 respiratory electron transport chain Effects 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
229960003962 trifluridine Drugs 0.000 description 2
230000029812 viral genome replication Effects 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
241000233866 Fungi Species 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
206010061137 Ocular toxicity Diseases 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
239000004264 Petrolatum Substances 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
206010044245 Toxic optic neuropathy Diseases 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
230000004075 alteration Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000007541 cellular toxicity Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
150000001869 cobalt compounds Chemical class 0.000 description 1
IVMYJDGYRUAWML-UHFFFAOYSA-N cobalt(ii) oxide Chemical class [Co]=O IVMYJDGYRUAWML-UHFFFAOYSA-N 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000001524 infective effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000009434 installation Methods 0.000 description 1
239000002502 liposome Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000002483 medication Methods 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
231100001228 moderately toxic Toxicity 0.000 description 1
231100000327 ocular toxicity Toxicity 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
229940066842 petrolatum Drugs 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
238000000053 physical method Methods 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
238000002962 plaque-reduction assay Methods 0.000 description 1
239000003586 protic polar solvent Substances 0.000 description 1
238000011555 rabbit model Methods 0.000 description 1
150000005838 radical anions Chemical class 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000008521 reorganization Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
229910052723 transition metal Inorganic materials 0.000 description 1
150000003624 transition metals Chemical class 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/06—Cobalt compounds
- C07F15/065—Cobalt compounds without a metal-carbon linkage
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Virology (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IL9772991A 1990-03-30 1991-03-29 Antiviral preparations containing organic metallic complexes IL97729A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/502,294 US5106841A (en)	1986-05-13	1990-03-30	Antiviral compositions and method for their use

Publications (2)

Publication Number	Publication Date
IL97729A0 IL97729A0 (en)	1992-06-21
IL97729A true IL97729A (en)	1996-01-31

Family

ID=23997182

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9772991A IL97729A (en)	1990-03-30	1991-03-29	Antiviral preparations containing organic metallic complexes

Country Status (9)

Country	Link
US (1)	US5106841A (de)
EP (1)	EP0522084B1 (de)
JP (1)	JP3179096B2 (de)
AT (1)	ATE175115T1 (de)
AU (1)	AU656521B2 (de)
CA (1)	CA2079482C (de)
DE (1)	DE69130705T2 (de)
IL (1)	IL97729A (de)
WO (1)	WO1991015212A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5258403A (en) *	1986-05-13	1993-11-02	Chai-Tech Corporation	Metallo-organic salt compounds and pharmaceutical uses thereof
US5756491A (en) *	1986-05-13	1998-05-26	Chai-Tech Corporation	Antiviral cobalt-organic compounds
US7582786B2 (en) *	1992-12-07	2009-09-01	Eukarion Inc.	Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US5696109A (en) *	1992-12-07	1997-12-09	Eukarion, Inc.	Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US5834509A (en) *	1992-12-07	1998-11-10	Eukarion, Inc.	Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US5403834A (en) *	1992-12-07	1995-04-04	Eukarion, Inc.	Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
WO1994013301A1 (en) *	1992-12-15	1994-06-23	Redox Pharmaceutical Corporation	Antiviral compositions and method for their use
US6008190A (en) *	1994-12-15	1999-12-28	California Institute Of Technology	Cobalt Schiff base compounds
CA2240183A1 (en) *	1995-12-12	1997-06-19	California Institute Of Technology	Cobalt schiff base compounds
BR9713368A (pt) *	1996-11-20	2001-09-18	Introgen Therapeutics Inc	Processo melhorado para a produção e a purificação de vetores adenovirais
US7732129B1 (en) *	1998-12-01	2010-06-08	Crucell Holland B.V.	Method for the production and purification of adenoviral vectors
AU8405298A (en) *	1997-07-16	1999-02-10	California Institute Of Technology	Methods of unfolding proteins using metal complexes
CA2706350A1 (en) *	1998-06-11	1999-12-16	Redox Pharmaceutical Corporation	Method of hiv and hpv prophylaxis
US6589948B1 (en) *	2000-11-28	2003-07-08	Eukarion, Inc.	Cyclic salen-metal compounds: reactive oxygen species scavengers useful as antioxidants in the treatment and prevention of diseases
AU2005334193A1 (en) *	2004-06-30	2007-02-22	Redox Pharmaceutical Corporation	Topical antiviral therapeutic and prophylactic treatment of adenoviruses and their associated diseases
EP1815029A4 (de) *	2004-11-03	2009-06-10	Introgen Therapeutics Inc	Neues verfahren zur herstellung und reinigung von adenovirusvektoren
US20100298415A1 (en) *	2009-03-23	2010-11-25	Northwestern University	Targeted schiff base complexes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3420865A (en) *	1966-05-12	1969-01-07	Colgate Palmolive Co	Novel carbocyclic ferrocenes
DE2527158A1 (de) *	1975-06-18	1976-12-23	Herz Eberhard	Arzneimittel zur behandlung von infektionskrankheiten und von nicht nachweisbar durch mikroorganismen ausgeloeste entzuendungen in der human- und veterinaermedizin
CA1218600A (en) *	1982-12-06	1987-03-03	Gerald L. Maurer	Methods and compositions for treating inflammation or arthritis
US4866053A (en) *	1986-05-13	1989-09-12	Chai-Tech Corporation	Method of treating a burn employing a metallo-organic cobalt compound
US5049557A (en) *	1986-05-13	1991-09-17	Chai-Tech Corporation	Metallo-organic salt compounds and pharmaceutical uses thereof

1990
- 1990-03-30 US US07/502,294 patent/US5106841A/en not_active Expired - Lifetime
1991
- 1991-03-28 DE DE69130705T patent/DE69130705T2/de not_active Expired - Fee Related
- 1991-03-28 EP EP91908127A patent/EP0522084B1/de not_active Expired - Lifetime
- 1991-03-28 AT AT91908127T patent/ATE175115T1/de not_active IP Right Cessation
- 1991-03-28 WO PCT/US1991/002146 patent/WO1991015212A1/en not_active Ceased
- 1991-03-28 CA CA002079482A patent/CA2079482C/en not_active Expired - Lifetime
- 1991-03-28 JP JP50761791A patent/JP3179096B2/ja not_active Expired - Lifetime
- 1991-03-28 AU AU76765/91A patent/AU656521B2/en not_active Expired
- 1991-03-29 IL IL9772991A patent/IL97729A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
EP0522084A1 (de)	1993-01-13
AU7676591A (en)	1991-10-30
JP3179096B2 (ja)	2001-06-25
ATE175115T1 (de)	1999-01-15
US5106841A (en)	1992-04-21
DE69130705T2 (de)	1999-06-10
JPH05507065A (ja)	1993-10-14
EP0522084A4 (en)	1993-03-24
CA2079482A1 (en)	1991-10-01
WO1991015212A1 (en)	1991-10-17
AU656521B2 (en)	1995-02-09
EP0522084B1 (de)	1998-12-30
CA2079482C (en)	2004-07-20
DE69130705D1 (de)	1999-02-11
IL97729A0 (en)	1992-06-21

Legal Events

Date	Code	Title
1996-07-23	FF	Patent granted
1997-08-14	KB	Patent renewed
2001-07-24	KB	Patent renewed
2005-07-25	MM9K	Patent not in force due to non-payment of renewal fees
2009-11-18	KB	Patent renewed
2011-12-29	EXP	Patent expired

Publication	Publication Date	Title
EP0522084B1 (de)	1998-12-30	Antivirale zusammensetzungen und verfahren zu ihrer anwendung
DE69709857T2 (de)	2002-08-29	Acridonderivate als antineoplastische-und antiretrovirale mittel
JPH0296524A (ja)	1990-04-09	抗癌活性を有する治療薬組成物と癌の治療方法
JP3524920B2 (ja)	2004-05-10	抗ウイルス組成物及びその使用方法
CA1078736A (en)	1980-06-03	Therapeutic application of 4-carbamoyl-5-hydroxyimidazole
US5210096A (en)	1993-05-11	Antiviral compositions and method for their use
CA1259918A (en)	1989-09-26	Resistance imparting agent for cold syndrome of low pulmonary function patients
EP0505226B1 (de)	1996-03-20	Sauerstoffradikalfänger
EP1075186B1 (de)	2010-11-24	Verfahren zur hsv-prophylaxe
US3322627A (en)	1967-05-30	Method of treating herpes simplex infections with 5-methylamino-2'-deoxyuridine, and compositions therefor
Remmers et al.	1964	Metal-Acid Complexes with Members of the Tetracycline Family I: Introduction
JPH02212425A (ja)	1990-08-23	緑内障の治療のためのアンギオテンシン変換酵素阻害剤とカルボネートデヒドラターゼ阻害剤との組合せ
CA2176392C (en)	2005-11-08	Use of 2-amino purine derivatives for the treatment and prophylaxis of human herpes virus 7 infection
JPS5951927B2 (ja)	1984-12-17	緑内障治療剤
KR100341737B1 (ko)	2002-11-25	인간헤르페스바이러스6감염의치료및예방용2-아미노푸린유도체의용도
JPH02218612A (ja)	1990-08-31	緑内障の治療におけるアンギオテンシン変換酵素阻害剤
EP0639978B1 (de)	1997-03-19	Pharmazeutische mischung mit antineoplastischer wirksamkeit
JPS63146839A (ja)	1988-06-18	プテロシン系化合物を含んで成る制癌剤
JPS6121452B2 (de)	1986-05-27
US6476013B1 (en)	2002-11-05	Method of chlamydia prophylaxis
CA2343824A1 (en)	1999-12-16	Method of hiv and hpv prophylaxis
JPH03255027A (ja)	1991-11-13	老人性白内障および糖尿病性白内障治療剤
EP0946168A1 (de)	1999-10-06	Verwendung von ethylendiamindisuccinat zur herstellung eines arzneimittels mit antiviralen eigenschaften
GB2056280A (en)	1981-03-18	Normolipidemic or platelet anti-binder
JPS6231689B2 (de)	1987-07-09